Ultragenyx 同意以 2.1 亿美元出售 FDA 优先审评券
Ultragenyx Pharmaceutical与买方达成了一项最终协议，以2.1亿美元的价格出售一项罕见儿科疾病优先审查凭证。该交易仍受常规交割条件的约束，包括适用的Hart-Scott-Rodino等待期的届满。
为什么重要. 此次出售可能为Ultragenyx提供大量非稀释性资金用于其药物开发项目，同时也展示了可转让FDA审评凭证的货币价值。
深度阅读深度解读
01
证据
- GGlobeNewswire public company news公司披露2026-10-07 20:30
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million.
- GGlobeNewswire public company news公司披露2026-10-07 20:30
NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. Ultragenyx received the PRV upon U.S.…
- GGlobeNewswire public company news公司披露2026-10-07 20:30
The closing of the PRV transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act.